alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
OSLDPS Information Bulletin

No. 00-21 October 26, 2000

TO: All State Administrative Agency Heads

All State Administrative Agency Points of Contact

FROM: C.H. Straub, II

Director

SUBJECT: Emergency Response to Terrorism: Job Aid

The Office for State and Local Domestic Preparedness Support (OSLDPS), the Federal Emergency

Management Agency (FEMA), the United States Fire Administration (USFA), and the National Fire

Academy (NFA) have designed and produced a comprehensive document intended to support training

messages of the Emergency Response to Terrorism NFA curriculum.

The Job Aid is designed to assist the first responder from the Fire, EMS, HazMat, and Law

Enforcement disciplines. This includes both tactical and strategic issues that range from line

personnel to unit officers and up to and including the Incident Commander. There are five primary

sections that are covered (each tabbed and color coded for rapid access of information): Introduction,

Operational Considerations, Incident-Specific Actions, Agency Related Issues, and the Glossary.

The document is not a training manual. It is expected that personnel already have appropriate training

and experience to address the identified tactics. It should serve as a reminder for those who already

have completed the appropriate level of tactical or strategic training, such as the Emergency Response

to Terrorism courses developed for classroom and self-study.

The document is designed to assist emergency response personnel in identifying a possible

terrorist/WMD incident and implementing initial actions. The document identifies both strategic and

tactical considerations that should be assessed within the first hour of an incident. Appropriate tactics

would then be implemented as required.

To order the ERT: JA, it is available in limited numbers (up to five each to response organizations,

one to individuals) from the NFA Publications or in bulk quantities from the Government Printing

Office through Alan Ptak at (202) 512-1709. Mr. Ptak’s e-mail address is aptak@gpo.gov. The

stock number is 064-000-00027.
§ 516.30 Annual reports for a MUMS-designated drug. Within 14 months after the date on which a MUMS drug is granted designation and annually thereafter until approval, the sponsor of a MUMS-designated drug shall submit a brief progress report on the drug to the investigational new animal drug file addressed to the Director of the Office of Minor Use and Minor Species Animal Drug Development that includes the following information: ( a ) A short account of the progress of drug development including a description of studies initiated, ongoing, and completed, and a short summary of the status or results of such studies;
( b ) A description of the investigational plan for the coming year, as well as any anticipated difficulties in development, testing, and marketing; and
( c ) A brief discussion of any changes that may affect the MUMS-designated drug status of the product. For example, situations in which testing data demonstrate that the proposed intended use is inappropriate due to unexpected issues of safety or effectiveness.
[Federal Register Volume 75, Number 36 (Wednesday, February 24, 2010)]
[Notices]
[Pages 8325-8326]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2010-3631]


-----------------------------------------------------------------------

DEPARTMENT OF ENERGY

Federal Energy Regulatory Commission

[Docket No. ER10-727-000]


AEP Retail Energy Partners, LLC; Supplemental Notice That Initial 
Market-Based Rate Filing Includes Request for Blanket Section 204 
Authorization

February 18, 2010.
    This is a supplemental notice in the above-referenced proceeding of 
AEP Retail Energy Partner, LLC's application for market-based rate 
authority, with an accompanying rate tariff, noting that such 
application includes a request for blanket authorization, under 18 CFR 
part 34, of future issuances of securities and assumptions of 
liability.
    Any person desiring to intervene or to protest should file with the 
Federal Energy Regulatory Commission, 888 First Street, NE., 
Washington, DC, 20426, in accordance with Rules 211 and 214 of the 
Commission's Rules of Practice and Procedure (18 CFR 385.211 and 
385.214). Anyone filing a motion to intervene or protest must serve a 
copy of that document on the Applicant.
    Notice is hereby given that the deadline for filing protests with 
regard to the applicant's request for blanket

[[Page 8326]]

authorization, under 18 CFR part 34, of future issuances of securities 
and assumptions of liability, is March 9, 2010.
    The Commission encourages electronic submission of protests and 
interventions in lieu of paper, using the FERC Online links at http://www.ferc.gov. To facilitate electronic service, persons with Internet 
access who will eFile a document and/or be listed as a contact for an 
intervenor must create and validate an eRegistration account using the 
eRegistration link. Select the eFiling link to log on and submit the 
intervention or protests.
    Persons unable to file electronically should submit an original and 
14 copies of the intervention or protest to the Federal Energy 
Regulatory Commission, 888 First St., NE., Washington, DC, 20426.
    The filings in the above-referenced proceeding are accessible in 
the Commission's eLibrary system by clicking on the appropriate link in 
the above list. They are also available for review in the Commission's 
Public Reference Room in Washington, DC. There is an eSubscription link 
on the Web site that enables subscribers to receive e-mail notification 
when a document is added to a subscribed dockets(s). For assistance 
with any FERC Online service, please e-mail <a href="/cdn-cgi/l/email-protection#9cdad9cedfd3f2f0f5f2f9cfe9ececf3eee8dcfaf9eeffb2fbf3ea"><span class="__cf_email__" data-cfemail="bff9faedfcf0d1d3d6d1daeccacfcfd0cdcbffd9dacddc91d8d0c9">[email protected]</span></a>. 
or call (866) 208-3676 (toll free). For TTY, call (202) 502-8659.

 Kimberly D. Bose,
Secretary.
[FR Doc. 2010-3631 Filed 2-23-10; 8:45 am]
BILLING CODE 6717-01-P


</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>
#### § 19.45 Temporary disqualification of former employees.

Within 1 year after termination of employment with the Food and Drug Administration, no former Food and Drug Administration employee, including a special government employee, shall appear personally before the Food and Drug Administration or other federal agency or court as agent or attorney for any person other than the United States in connection with any proceeding or matter in which the United States is a party or has a direct and substantial interest and which was under his official responsibility at any time within one year preceding termination of such responsibility. The term *official responsibility* means the direct administrative or operating authority, whether intermediate or final, and either exercisable alone or with others, and either personally or through subordinates, to approve, disapprove, or otherwise direct government action.
###### Editorial Note on Part 201

#### Editorial Note:

Nomenclature changes to part 201 appear at 69 FR 13717, Mar. 24, 2004.

#### § 201.315 Over-the-counter drugs for minor sore throats; suggested warning.

The Food and Drug Administration has studied the problem of the labeling of lozenges or troches containing a local anesthetic, chewing gum containing aspirin, various mouth washes and gargles and other articles sold over the counter for the relief of minor irritations of the mouth or throat. It will not object to the labeling of suitable articles of this type “For the temporary relief of minor sore throats”, provided this is immediately followed in the labeling with a warning statement in prominent type essentially as follows: “Warning—Severe or persistent sore throat or sore throat accompanied by high fever, headache, nausea, and vomiting may be serious. Consult physician promptly. Do not use more than 2 days or administer to children under 3 years of age unless directed by physician.”
<TABLE> <S> <C>

<PAGE>
 
<ARTICLE> 5
<LEGEND>
THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED FROM THE
QUARTERLY REPORT 10-Q AND IS QUALIFIED IN ITS ENTIRETY BY REFERENCE TO SUCH
FINANCIAL STATEMENTS.
</LEGEND>
<CIK> 0000813807
<NAME> COURTYARD BY MARRIOTT LIMITED PARTNERSHIP
<MULTIPLIER> 1,000
<CURRENCY> U.S. DOLLAR
       
<S>                             <C>
<PERIOD-TYPE>                   6-MOS
<FISCAL-YEAR-END>                          DEC-31-1997
<PERIOD-START>                             JAN-01-1997
<PERIOD-END>                               JUN-20-1997
<EXCHANGE-RATE>                                   1.00
<CASH>                                          10,051
<SECURITIES>                                         0
<RECEIVABLES>                                    9,244
<ALLOWANCES>                                         0
<INVENTORY>                                          0
<CURRENT-ASSETS>                                18,327
<PP&E>                                         516,736
<DEPRECIATION>                               (216,090)
<TOTAL-ASSETS>                                 338,268
<CURRENT-LIABILITIES>                           27,678
<BONDS>                                        337,171
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                             0
<OTHER-SE>                                    (26,581)
<TOTAL-LIABILITY-AND-EQUITY>                   338,268
<SALES>                                              0
<TOTAL-REVENUES>                                46,190
<CGS>                                                0
<TOTAL-COSTS>                                        0
<OTHER-EXPENSES>                                23,837
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                              11,693
<INCOME-PRETAX>                                 10,660
<INCOME-TAX>                                         0
<INCOME-CONTINUING>                                  0
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                 12,473
<CHANGES>                                            0
<NET-INCOME>                                    23,133
<EPS-PRIMARY>                                        0
<EPS-DILUTED>                                        0
        

</TABLE>
Editorial Note on Part 189
Editorial Note: Nomenclature changes to part 189 appear at 61 FR 14482, Apr. 2, 1996; 66 FR 56035, Nov. 6, 2001; 70 FR 40880, July 15, 2005; and 70 FR 67651, Nov. 8, 2005.

§ 189.135 Cyclamate and its derivatives. ( a ) Calcium, sodium, magnesium and potassium salts of cyclohexane sulfamic acid, (C6H12NO3S)2Ca, (C6H12NO3S)Na, (C6H12NO3S)2Mg, and (C6H12NO3S)K. Cyclamates are synthetic chemicals having a sweet taste 30 to 40 times that of sucrose, are not found in natural products at levels detectable by the official methodology, and have been used as artificial sweeteners.
( b ) Food containing any added or detectable level of cyclamate is deemed to be adulterated in violation of the act based upon an order published in the Federal Register of October 21, 1969 (34 FR 17063).
( c ) The analytical methods used for detecting cyclamate in food are in sections 20.162-20.172 of the “Official Methods of Analysis of the Association of Official Analytical Chemists,” 13th Ed. (1980), which is incorporated by reference. Copies may be obtained from the AOAC INTERNATIONAL, 481 North Frederick Ave., suite 500, Gaithersburg, MD 20877, or may be examined at the National Archives and Records Administration (NARA). For information on the availability of this material at NARA, call 202-741-6030, or go to: *http://www.archives.gov/federal_register/code_of_federal_regulations/ibr_locations.html .*
[42 FR 14659, Mar. 15, 1977, as amended at 49 FR 10114, Mar. 19, 1984; 54 FR 24899, June 12, 1989]
----

----

| 1. Execution date      | July 7, 2011                                                                                                                                                                                                  |
|------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 2. Previous Owners     | Messers. Vasco Grendene, Giovanni Polonio and Sergio Bianchi and Ms. Angelina Rondanin                                                                                                                        |
| 3. Current Owner       | Solemax                                                                                                                                                                                                       |
| 4. Portion of the land | Municipality of Canaro (RO), sheet 9, parcels 115, 117 and 119; sheet 10, parcels 16, 153, 155 and 159, size 11.57.87 hectares.                                                                               |
| 5. Duration            | 21 years (until June 30, 2032)                                                                                                                                                                                |
| 6. Consideration       | As consideration for the 21-year building right, Soleco paid an amount of Euro 662,822.11. This consideration has been fully paid upon execution and acknowledgement of such payment is included in the deed. |
| 7. Easements           | An electric easement right is in place in favour of Enel on parcels 16 and 159.                                                                                                                               |
| 8. Competent Court     | Exclusive jurisdiction of the court of Rovigo.                                                                                                                                                                |

----

1 The original language version is on file with the Registrant and is available upon request.

----

----
Editorial Note on Part 201
Editorial Note: Nomenclature changes to part 201 appear at 69 FR 13717, Mar. 24, 2004.

§ 201.310 Phenindione; labeling of drug preparations intended for use by man. ( a ) Reports in the medical literature and data accumulated by the Food and Drug Administration indicate that phenindione, a synthetic anticoagulant drug, has caused a number of cases of agranulocytosis (with two fatalities). There are also reports implicating the drug in cases of hepatitis and hypersensitivity reactions. In view of the potentially serious effects found to be associated with preparations of this drug intended for use by man, the Commissioner of Food and Drugs will regard such preparations as misbranded within the meaning of section 502(f) (1) and (2) of the Federal Food, Drug, and Cosmetic Act, unless the label and labeling on or within the package from which the drug is to be dispensed, and any other labeling furnishing or purporting to furnish information for use of the drug, bear a conspicuous warning statement to the following effect: “Warning: Agranulocytosis and hepatitis have been associated with the use of phenindione. Patients should be instructed to report promptly prodromal symptoms such as marked fatigue, chill, fever, and sore throat. Periodic blood studies and liver function tests should be performed. Use of the drug should be discontinued if leukopenia occurs or if evidence of hypersensitivity, such as dermatitis or fever, appears.”
( b ) Regulatory action may be initiated with respect to preparations of phenindione intended for use by man found within the jurisdiction of the act on or after November 25, 1961, unless such preparations are labeled in accordance with paragraph (a) of this section.
# L_2019027EN.01003101.xml

| 31.1.2019 | EN | Official Journal of the European Union | L 27/31 |
| --- | --- | --- | --- |

31.1.2019

EN

Official Journal of the European Union

L 27/31

---

COUNCIL DECISION (EU) 2019/152

of 28 January 2019

appointing a member, proposed by the Kingdom of Belgium, of the Committee of the Regions

THE COUNCIL OF THE EUROPEAN UNION,

Having regard to the Treaty on the Functioning of the European Union, and in particular Article 305 thereof,

Having regard to the proposal of the Belgian Government,

Whereas:

| (1) | On 26 January 2015, 5 February 2015 and 23 June 2015, the Council adopted Decisions (EU) 2015/116 (1), (EU) 2015/190 (2) and (EU) 2015/994 (3) appointing the members and alternate members of the Committee of the Regions for the period from 26 January 2015 to 25 January 2020. |
| --- | --- |

(1)

On 26 January 2015, 5 February 2015 and 23 June 2015, the Council adopted Decisions (EU) 2015/116 (1), (EU) 2015/190 (2) and (EU) 2015/994 (3) appointing the members and alternate members of the Committee of the Regions for the period from 26 January 2015 to 25 January 2020.

| (2) | A member's seat on the Committee of the Regions has become vacant following the end of the mandate on the basis of which Mr Alain HUTCHINSON (Conseiller communal et échevin à Saint-Gilles) was proposed, |
| --- | --- |

(2)

A member's seat on the Committee of the Regions has become vacant following the end of the mandate on the basis of which Mr Alain HUTCHINSON (Conseiller communal et échevin à Saint-Gilles) was proposed,

HAS ADOPTED THIS DECISION:

Article 1

The following is hereby appointed as a member of the Committee of the Regions for the remainder of the current term of office, which runs until 25 January 2020:

| — | Mr Alain HUTCHINSON, Commissaire pour l'Europe et l'accueil des organisations internationales (change of mandate). |
| --- | --- |

—

Mr Alain HUTCHINSON, Commissaire pour l'Europe et l'accueil des organisations internationales (change of mandate).

Article 2

This Decision shall enter into force on the date of its adoption.

Done at Brussels, 28 January 2019.

For the Council

The President

P. DAEA

---

(1)  Council Decision (EU) 2015/116 of 26 January 2015 appointing the members and alternate members of the Committee of the Regions for the period from 26 January 2015 to 25 January 2020 (OJ L 20, 27.1.2015, p. 42).

1

(2)  Council Decision (EU) 2015/190 of 5 February 2015 appointing the members and alternate members of the Committee of the Regions for the period from 26 January 2015 to 25 January 2020 (OJ L 31, 7.2.2015, p. 25).

2

(3)  Council Decision (EU) 2015/994 of 23 June 2015 appointing the members and alternate members of the Committee of the Regions for the period from 26 January 2015 to 25 January 2020 (OJ L 159, 25.6.2015, p. 70).

3

---
§ 1302.08 False labeling of anabolic steroids. ( a ) It shall be unlawful to import, export, manufacture, distribute, dispense, or possess with intent to manufacture, distribute, or dispense, an anabolic steroid or product containing an anabolic steroid, unless the steroid or product bears a label clearly identifying an anabolic steroid or product containing an anabolic steroid by the nomenclature used by the International Union of Pure and Applied Chemistry (IUPAC).
( b ) ( 1 ) A product described in paragraph (b)(2) of this section is exempt from the International Union of Pure and Applied Chemistry nomenclature requirement of this section if such product is labeled in the manner required under the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 301 *et seq.*).
( 2 ) A product is described in this paragraph (b)(2) if the product— ( i ) Is the subject of an approved application as described in section 505(b) or (j) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355(b), (j)); or
( ii ) Is exempt from the provisions of section 505 of the Federal Food, Drug, and Cosmetic Act relating to new drugs because— ( A ) It is intended solely for investigational use as described in section 505(i) of the Federal Food, Drug, and Cosmetic Act; and
( B ) Such product is being used exclusively for purposes of a clinical trial that is the subject of an effective investigational new drug application.
[88 FR 50040, Aug. 1, 2023]
<PAGE>   1
                                                                    EXHIBIT 23.1

                       CONSENT OF INDEPENDENT ACCOUNTANTS



We hereby consent to the incorporation by reference in this Registration
Statement on Form S-1 of our reports dated May 19, 1999, except for the last
paragraph of Note 8 which is as of June 22, 1999 and the first paragraph of
Note 12 which is as of August 27, 1999, relating to the financial statements
and financial statement schedule of Vixel Corporation which appear in Vixel
Corporation's Form S-1 registration statement (File No. 333-81347). We also
consent to the references to us under the headings "Experts" and "Selected
Financial Data" in Vixel Corporation's Form S-1 registration statement (File
No. 333-81347).


PricewaterhouseCoopers LLP
Seattle, Washington
September 28, 1999
§ 20.65 National defense and foreign policy. ( a ) Records or information may be withheld from public disclosure if they are: ( 1 ) Specifically authorized under criteria established by an Executive order to be kept secret in the interest of national defense or foreign policy; and
( 2 ) In fact properly classified under such Executive order.
( b ) [Reserved]
[70 FR 41958, July 21, 2005]
<TABLE> <S> <C>

<ARTICLE> 5
<MULTIPLIER> 1,000
       
<S>                             <C>
<PERIOD-TYPE>                   YEAR
<FISCAL-YEAR-END>                          JUN-30-1998
<PERIOD-START>                             JUL-01-1997
<PERIOD-END>                               JUN-30-1998
<CASH>                                           7,234
<SECURITIES>                                     6,674
<RECEIVABLES>                                    3,400
<ALLOWANCES>                                         0
<INVENTORY>                                         40
<CURRENT-ASSETS>                                17,689
<PP&E>                                           6,434
<DEPRECIATION>                                   5,434
<TOTAL-ASSETS>                                  24,153
<CURRENT-LIABILITIES>                            9,540
<BONDS>                                              0
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                            54
<OTHER-SE>                                      14,545
<TOTAL-LIABILITY-AND-EQUITY>                    14,599
<SALES>                                          9,647
<TOTAL-REVENUES>                                18,346
<CGS>                                            1,778
<TOTAL-COSTS>                                    5,083
<OTHER-EXPENSES>                                14,653
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                                   0
<INCOME-PRETAX>                                  (644)
<INCOME-TAX>                                       907
<INCOME-CONTINUING>                            (1,551)
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                   (1,551)
<EPS-PRIMARY>                                    (.30)
<EPS-DILUTED>                                    (.30)
        

</TABLE>